Since mTOR inhibitors (e.g., rapamycin and everolimus) have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of facial angiofibromas in patients with tuberous sclerosis complex, and our above findings revealed the key role of mTORC1 signaling in the pathogenesis of rosacea, we wondered whether inhibition of mTORC1 was able to alleviate rosacea‐associated symptoms in rosacea patients. This evidence concerns the gene MTOR and rosacea.